Larazotide (AT-1001)
Larazotide (AT-1001) is a healing & repair peptide used in evidence-based, physician-supervised protocols. First-line for leaky gut, celiac disease, non-celiac gluten sensitivity, IBD.
What is Larazotide (AT-1001)?
8-AA tight junction regulator. Blocks zonulin receptor, prevents actin-myosin complex disassembly, directly seals intestinal tight junctions. Reduces intestinal permeability without systemic absorption. ADMINISTRATION: Oral submucosal — dissolve in small amount of water, swish and hold 60-90 seconds.
Uses & clinical decision logic
First-line for leaky gut, celiac disease, non-celiac gluten sensitivity, IBD. Run 6-8 week cycles.
Larazotide (AT-1001) dosage & administration
| Vial size | BAC water | Dosing range | Units / dose | Frequency | Route |
|---|---|---|---|---|---|
| 5mg | 2mL bacteriostatic saline | 0.5-1mg | 0.2-0.4mL | 1-2x/day before meals | Oral (submucosal) |
Safety & contraindications
Not for IV or SubQ use.
Stacking & combinations
Synergistic with BPC-157 (angiogenic mucosal healing) and KPV (anti-inflammatory mucosal support) for complete gut repair trifecta.
Related peptides
Frequently asked questions
What is Larazotide (AT-1001) used for?
First-line for leaky gut, celiac disease, non-celiac gluten sensitivity, IBD. Run 6-8 week cycles.
What is the typical Larazotide (AT-1001) dosage?
Common dosing ranges from 0.5-1mg (1-2x/day before meals, Oral (submucosal)). Exact dosing is individualized and set by a licensed physician.
How is Larazotide (AT-1001) administered?
Larazotide (AT-1001) is typically administered via Oral (submucosal).
What are the contraindications for Larazotide (AT-1001)?
Not for IV or SubQ use.
Build a physician-supervised protocol around your goal — no gatekeeping, real doctors, 503A compounding pharmacies.
Build your protocol →This page is for educational purposes only and is not medical advice. Peptide therapies described here are provided under physician supervision through 503A compounding pharmacies. Many peptides are not FDA-approved for the uses described. Do not start, stop, or change any protocol without consulting a licensed physician.